Haisco(002653) 2 1 Shi Ji Jing Ji Bao Dao·2025-05-16 01:58Group 1: Regulatory Developments - The National Health Commission reported the dismissal of a doctor from Japan-China Friendship Hospital for violating medical ethics and safety protocols during a surgery [1] - The approval of a new analgesic drug, Anrekefen injection, by the National Medical Products Administration (NMPA) for treating postoperative pain [3] - The approval of Pyrotinib tablets by NMPA for treating specific types of breast cancer in adults [4] Group 2: Strategic Partnerships - Hainan Haiyao signed a strategic cooperation framework agreement with Aikang International Group to enhance regional economic cooperation and expand in the health sector [7] - Stone Pharmaceutical Group entered into an exclusive licensing agreement with Cipla for the commercialization of Irinotecan liposome injection in the U.S., with potential payments totaling up to $10.25 billion [9] Group 3: Market Activity - Xinghao Pharmaceutical received FDA approval for its docetaxel injection, which is used in the treatment of various cancers [5] - Jiao Da Ang Li announced abnormal stock trading activity, with a cumulative price increase deviation exceeding 20% over two trading days, while confirming normal operational conditions [12]